Update -- dyadic advancing proprietary owned covid-19 vaccine candidate, dyai-100, towards human clinical trial

Jupiter, fla., march 29, 2021 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on further improving, applying and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today is updating the market on the progress made in certain of its coronavirus (covid-19) and other infectious disease programs.
DYAI Ratings Summary
DYAI Quant Ranking